Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Announce Cancer Vaccine Combinations Presented at ESMO

European Society of Medical Oncology Congress Presentations Show B-Cell Vaccine Combinations Inhibit Cancer Growth in Preclinical Models

SYDNEY, Australia, 1 October 2019
: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced two presentations by medical investigators at the European Society of Medical Oncology in Barcelona Spain showed combining its HER2 vaccines with PD1 vaccines reduced cancer growth in a number of standard preclinical models.

For further information please download the attached PDF:
Download this document